DeutschNewstral
Article
jdsupra.com on 2016-11-01 22:50
ABBVIE V. AMGEN: Amgen Agrees To Comply With The BPCIA Notice Of Commercial Marketing Requirements
Related news
- Amgen and AbbVie Settle Adalimumab BPCIA Litigationjdsupra.com
- BPCIA: Amgen Begins the Patent Dance With AbbViejdsupra.com
- Apotex Accuses Amgen of Sham BPCIA Litigationjdsupra.com
- Amgen and Sandoz Settle Denosumab BPCIA Litigationjdsupra.com
- PAmgen settles with AbbVie over Humira biosimilarpacbiztimes.com
- New BPCIA Litigation: Amgen v. Coherus (D. Del.)jdsupra.com
- Amgen Sues Coherus Under BPCIA After Completing Patent Dancejdsupra.com
- New BPCIA Complaint: Amgen Sues Pfizer over Proposed Filgrastim Biosimilarjdsupra.com
- BPCIA Helps Amgen Gain Dismissal of Genentech Complaintjdsupra.com
- Amgen Sues Hospira in Fourth Lawsuit Under the BPCIAjdsupra.com
- New BPCIA Litigation: Amgen v. Mylan (W.D. Pa.)jdsupra.com
- Motion to Dismiss Denied in Amgen v. Hospira BPCIAjdsupra.com
- New BPCIA Complaint: Genentech Sues Amgen over Proposed Trastuzumab Biosimilarjdsupra.com
- Amgen and Hospira Square Off Over BPCIA Private Right of Action After Amgen v. Apotex Rulingjdsupra.com
- Litigation Update: Answer Filed in AbbVie v. Amgenjdsupra.com
- AbbVie Sues Amgen On 10 Of 100 Humira Patentsjdsupra.com
- AbbVie Sues Amgen to Prevent Launch of Humira Biosimilarjdsupra.com
- PAmgen settles with AbbVie over Humira biosimilar litigationpacbiztimes.com
- Coherus Settles with AbbVie, and Sues Amgen, Over Adalimumab Biosimilarsjdsupra.com
- Supreme Court to Consider BPCIA Requirements for Biosimilarsjdsupra.com